Access to Vaccines Index 2017
The Index finds a high level of diversity in how vaccine companies are improving access to vaccines for people living in poorer countries. GSK leads the three areas evaluated, with a strong performance from Sanofi across the board…
06 Mar 2017
02 Nov 2016
06 Jan 2016
Detailed breakdown of each company’s access performances and opportunities to do more, as well as portfolio and pipeline analyses.
How are vaccine companies responding to key global health challenges? Looking at how the first malaria and dengue vaccines are being deployed; and responses to emerging infectious diseases such as Ebola and Zika virus.
“Disease outbreaks will continue to occur.
Companies need to be at the table as governments and others work to build resilient health systems.”
Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.
R&D for vaccine adaptations
Adaptations to existing vaccines account for half of vaccine R&D projects
Index identifies wide variety of adaptations in the pipeline, together accounting for 48% of R&D projects…
When setting prices, all companies consider countries’ Gavi status – most also consider GNI per capita
Companies report considering 18 factors when setting vaccine prices, including development costs and the public health value of the vaccine…
Aligning supply and demand
Companies take diverse approaches to aligning supply with demand
Companies take diverse approaches to aligning supply with demand, with four companies taking comparatively strong approaches…
The Access to Vaccines Index is funded by
The Access to Medicine Foundation is funded by